Sugi Predict

Sugi Predict / Compounds / SCHEMBL29611191

SCHEMBL29611191

SCHEMBL29611191

CN(C(=O)OCC1c2ccccc2-c2ccccc21)[C@@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 15/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ MDM4 O15151 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ FABP5 Q01469 2/20 0.38
▸ FABP7 O15540 1/20 0.38
▸ DNMT1 P26358 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409339 1.00 KIF11 (0.40) KIF11KMT2AMDM4TP53FABP5
SCHEMBL31714132 1.00 KIF11 (0.40) KIF11KMT2AMDM4TP53FABP5
SCHEMBL29511437 1.00 KIF11 (0.40) KIF11KMT2AMDM4TP53FABP5
SCHEMBL23722969 1.00 KIF11 (0.40) KIF11KMT2AMDM4TP53FABP5
SCHEMBL31370691 0.93 KIF11 (0.52) KIF11MDM4TP53FABP5DNMT1
SCHEMBL30471578 0.93 KIF11 (0.52) KIF11MDM4TP53FABP5DNMT1
SCHEMBL2814403 0.90 FABP5 (0.39) KIF11KMT2AMDM4TP53FABP5
SCHEMBL2814407 0.90 FABP5 (0.39) KIF11KMT2AMDM4TP53FABP5
SCHEMBL4406592 0.88 KIF11 (0.39) KIF11KMT2AMDM4TP53FABP5
SCHEMBL4406195 0.87 MDM4 (0.39) KIF11KMT2AMDM4TP53FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022183740-A1 METHOD FOR PREPARING PANCREATIC BETA CELL, AND USE THEREOF 贝康医学科技有限公司 2022-09-09 — — WO claimed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 — — EP disclosed
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2026-01-22 — — US disclosed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
US-20250332300-A1 HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2025-10-30 — — US disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 — — WO disclosed
EP-3728289-B1 OPTIMISED COMPOUNDS Axelia Oncology Pty Ltd (AU) 2025-09-10 — — EP disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 — — US disclosed
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2025-05-22 — — US disclosed
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-12 — — US disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 — — US disclosed
US-11912794-B2 Modulation of structured polypeptide specificity Bicyclerd Limited (GB) 2024-02-27 — — US disclosed
US-20240010684-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2024-01-11 — — US disclosed
CN-112980771-B Method for preparing pancreatic beta cells and application thereof 贝康医学科技有限公司 2023-12-19 — — CN disclosed
US-11753444-B2 Modulation of structured polypeptide specificity Bicyclerd Limited (GB) 2023-09-12 — — US disclosed
WO-2023122945-A1 CYCLIC POLYPEPTIDE COMPOUNDS AND USES THEREOF 知和(山东)大药厂有限公司 2023-07-06 — — WO disclosed
US-11667675-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2023-06-06 — — US disclosed
WO-2022183740-A1 METHOD FOR PREPARING PANCREATIC BETA CELL, AND USE THEREOF 贝康医学科技有限公司 2022-09-09 — — WO disclosed
EP-4011904-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF Bayer Aktiengesellschaft (DE) 2022-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 KIF11 4273/4885KMT2A 4690/4885MDM4 2629/4885
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KIF11 2771/4885KMT2A 2735/4885MDM4 1009/4885
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KIF11 3797/4885KMT2A 1052/4885MDM4 3040/4885
US-11667675-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 KIF11 4273/4885KMT2A 4690/4885MDM4 2629/4885
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KIF11 3239/4885KMT2A 2325/4885MDM4 1149/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KIF11 3177/4885KMT2A 2293/4885MDM4 1128/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 KIF11 4273/4885KMT2A 4690/4885MDM4 2629/4885
US-20250332300-A1 HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF ERBB2, EGFR, ERBB3 KIF11 4111/4885KMT2A 3524/4885MDM4 2510/4885
US-11753444-B2 Modulation of structured polypeptide specificity KLKB1, KLK5, KLK1 KIF11 1168/4885KMT2A 3367/4885MDM4 3079/4885
US-20240010684-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SPINT2, SERPINB1 KIF11 4338/4885KMT2A 4666/4885MDM4 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.